Santiago-Walker, A.: search on Z-Library

The world's largest scientific articles store. 70,000,000+ articles for free.

1

603TiP Phase II, open-label study of erdafitinib in adult and adolescent patients (pts) with advanced solid tumours harboring fibroblast growth factor receptor (FGFR) gene alterations

Schuler, M., Tabernero, J., Massard, C., Iyer, G. Vasudeva, Witt, O., Doi, T., Qin, S., Lu-Emerson, C., Hargrave, D., Garcia-Corbacho, J., Little, S., Xia, Q., Santiago-Walker, A., Moy, C.H., Hammond,

Journal:

Annals of Oncology

Year:

2020

File:

PDF, 119 KB

2020

2

Safety and activity of the pan–fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients with advanced urothelial carcinoma

Soria, J-C., Italiano, A., Cervantes, A., Tabernero, J., Infante, J., Lara, P.N., Spira, A., Calvo, E., Moreno, V., Blay, J-Y., Lauer, R., Chan, N., Zhong, B., Santiago-Walker, A. Ademi, Bussolari, J.

Journal:

Annals of Oncology

Year:

2016

Language:

english

File:

PDF, 43 KB

english, 2016

3

184TiPFIND: A phase II study to evaluate the efficacy of erdafitinib in FGFR-altered squamous NSCLC

Nogova, L, Malchers, F, Hillmer, A, Merkelbach-Bruse, S, Pinto, A, Woempner, C, Riedel, R, Scheffler, M, Michels, S, Porre, P De, Santiago-Walker, A, Fischer, R N, Abdulla, D S, Thomas, R, Buettner, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

4

Ongoing phase 2 study of erdafitinib (JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (M/UR UC) and FGFR gene alterations

Siefker-Radtke, A.O., Mellado, B., Decaestecker, K., Burke, J.M., O'Hagan, A., Avadhani, A., Zhong, B., Santiago-Walker, A., De Porre, P., Brookman-May, S., Garcia-Donas, J.

Journal:

Annals of Oncology

Year:

2016

Language:

english

File:

PDF, 42 KB

english, 2016

5

758P Assessment of prognostic and predictive value of FGFR alterations (FGFRa) in a real-world cohort of patients (pts) with high-risk pT1 non-muscle-invasive bladder cancer (NMIBC)

Breyer, J., Monga, M., Mayr, R., Otto, W., Burger, M., Eckstein, M., StÃ¶hr, R., Erben, P., Bolenz, C., Eidt, S., Sundaram, R., Baig, M., Galluzzi, A., Wirtz, R., Hartmann, A., Santiago-Walker, A.

Journal:

Annals of Oncology

Year:

2020

File:

PDF, 119 KB

2020

6

A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors

Aghajanian, Carol, Bell-McGuinn, Katherine M., Burris, Howard A., Siu, Lillian L., Stayner, Lee-Ann, Wheler, Jennifer J., Hong, David S., Kurkjian, Carla, Pant, Shubham, Santiago-Walker, Ademi, Gauvin

Journal:

Investigational New Drugs

Year:

2018

Language:

english

File:

PDF, 583 KB

english, 2018

7

Protein Kinase C Stimulates Apoptosis by Initiating G1 Phase Cell Cycle Progression and S Phase Arrest

Santiago-Walker, A. E., Fikaris, A. J., Kao, G. D., Brown, E. J., Kazanietz, M. G., Meinkoth, J. L.

Journal:

Journal of Biological Chemistry

Year:

2005

Language:

english

File:

PDF, 1.02 MB

english, 2005

8

Utility of a targeted NGS oncology assay for circulating tumor DNA in a multi-histology clinical setting

Eerkes, T., Santiago-Walker, A. Ademi, Loreen, M., Lim, L., Hernandez, J., Raymond, C., Henderson, S., Dipasquo, D., Shaffer, T., Motely, C., Moy, C., Wallace, S., Eaton, K., Karkera, J., Li, M.

Journal:

Annals of Oncology

Year:

2016

Language:

english

File:

PDF, 35 KB

english, 2016

9

P1.01-72 FIND Trial: A Phase II Study to Evaluate the Efficacy of the FGFR-Inhibitor Erdafitinib in FGFR-Mutated and -Translocated Squamous NSCLC

Nogova, L., Malchers, F., Zadoyan, G., Hillmer, A., Merkelbach-Bruse, S., Riedel, R., Michels, S., Kharabi Masouleh, B., De Porre, P., Santiago-Walker, A., Scheffler, M., Fischer, R., Abdulla, D., Tho

Journal:

Journal of Thoracic Oncology

Year:

2018

Language:

english

File:

PDF, 124 KB

english, 2018

10

Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib

Karkera, Jayaprakash D., Martinez Cardona, Gabriela, Bell, Katherine, Gaffney, Dana, Portale, Joseph C., Santiago-Walker, Ademi, Moy, Christopher, King, Peter, Sharp, Michael, Bahleda, Rastilav, Luo,

Journal:

Molecular Cancer Therapeutics

Year:

2017

Language:

english

File:

PDF, 1.97 MB

english, 2017

11

757P An observational study of outcomes of patients (pts) with advanced urothelial carcinoma (UC) after anti-programmed death-(Ligand) 1 (PD-[L]1) therapy by fibroblast growth factor receptor gene alteration (FGFRa) status

Rezazadeh, A., Loriot, Y., Papantoniou, D., Siefker-Radtke, A.O., Necchi, A., Naini, V., Santiago-Walker, A., Galluzzi, A., Monga, M., Burgess, E.F.

Journal:

Annals of Oncology

Year:

2020

File:

PDF, 122 KB

2020

12

The Ups and Downs of Transcription Factors in Melanoma

Santiago-Walker, A., Herlyn, M.

Journal:

JNCI Journal of the National Cancer Institute

Year:

2010

Language:

english

File:

PDF, 74 KB

english, 2010

13

920TiPErdafitinib compared with vinflunine or docetaxel or pembrolizumab in patients (pts) with metastatic or surgically unresectable (M/UR) urothelial carcinoma (UC) and selected fgfr gene alterations (FGFRalt): The phase III THOR study

Loriot, Y, Necchi, A, Park, S H, Huddart, R A, Burgess, E, Zhong, B, Santiago-Walker, A, Little, S, Roccia, T, De Porre, P, Siefker-Radtke, A O

Journal:

Annals of Oncology

Year:

2018

File:

PDF, 94 KB

2018

14

Correlation of BRAF mutation status in circulating-free DNA and tumor and association with clinical outcome across four BRAFi and MEKi clinical trials

Santiago-Walker, A., Gagnon, R., Mazumdar, J., Casey, M., Long, G. V., Schadendorf, D., Flaherty, K. T., Kefford, R. F., Hauschild, A., Hwu, P., Haney, P., O'Hagan, A., Carver, J., Goodman, V., Legos,

Journal:

Clinical Cancer Research

Year:

2015

Language:

english

File:

PDF, 1.20 MB

english, 2015

15

Melanocytes: From Morphology to Application

Santiago-Walker, A., Li, L., Haass, N.K., Herlyn, M.

Journal:

Skin Pharmacology and Applied Skin Physiology

Year:

2009

Language:

english

File:

PDF, 720 KB

english, 2009

16

Analysis of circulating tumor DNA (ctDNA) from the phase II BLC2001 trial of erdafitinib in locally advanced or metastatic urothelial carcinoma (mUC) to identify markers of intrinsic resistance to fibroblast growth factor receptor (FGFR)-targeted therapy

Siefker-Radtke, A.O., Loriot, Y., Necchi, A., Huddart, R.A., Burgess, E.F., Rezazadeh, A., O'Hagan, A., De Porre, P., Avadhani, A., Monga, M., Cherkas, Y., Moy, C.H., Santiago-Walker, A.

Journal:

Annals of Oncology

Year:

2020

File:

PDF, 79 KB

2020

17

Tenascin-C promotes melanoma progression by maintaining the ABCB5-positive side population

Fukunaga-Kalabis, M, Martinez, G, Nguyen, T K, Kim, D, Santiago-Walker, A, Roesch, A, Herlyn, M

Journal:

Year:

2010

Language:

english

File:

PDF, 1.06 MB

english, 2010

18

Matricellular Proteins Produced by Melanocytes and Melanomas: In Search for Functions

Mizuho Fukunaga-Kalabis, Ademi Santiago-Walker, Meenhard Herlyn

Journal:

Cancer Microenvironment

Year:

2008

Language:

english

File:

PDF, 252 KB

english, 2008

To build up a library is to create a life. It’s never just a random collection of books.

— Carlos María Domínguez

Official channel

Z-Library Desktop Launcher

Z-Library Since 2009 support@1delivery.pm

EnglishРусскийEspañolItalianoελληνικάاللغة العربيةBahasa IndonesiaBahasa Malaysiaहिन्दीDeutschFrançaisPortuguêsУкраїнськаPolski中文繁體中文日本語Tiếng ViệtAzərbaycan DiliՀայոց լեզուภาษาไทยTürk Diliქართველიবাংলাپښتوతెలుగుاردو한국어SrpskiБългарски